TrialBMC cancer2026

Nivolumab for unresectable cutaneous epithelial malignancies: an open-label, single-arm, multi-centre, phase II trial (NMSC-PD1).

Yoshio Nakamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.